Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Glucokise (Hexokise D or Hexokise 4 or GCK or EC 2.7.1.2) - Overview
Glucokise (Hexokise D or Hexokise 4 or GCK or EC 2.7.1.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glucokise (Hexokise D or Hexokise 4 or GCK or EC 2.7.1.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glucokise (Hexokise D or Hexokise 4 or GCK or EC 2.7.1.2) - Companies Involved in Therapeutics Development
AstraZeneca Plc
Eli Lilly and Co
Hua Medicine Shanghai Ltd
Impetis Biosciences Ltd
Kriya Therapeutics Inc
Ligand Pharmaceuticals Inc
Merck & Co Inc
Pfizer Inc
Sanwa Kagaku Kenkyusho Co Ltd
vTv Therapeutics Inc
Glucokise (Hexokise D or Hexokise 4 or GCK or EC 2.7.1.2) - Drug Profiles
AZD-1656 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dorzagliatin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Glucokise and Insulin for Diabetes and Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GKM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KTA-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-2608204 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-04937319 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Glucokise for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Glucokise for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules 1 to Activate Glucokise for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Glucokise for Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Glucokise for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Glucokise for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTP-399 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glucokise (Hexokise D or Hexokise 4 or GCK or EC 2.7.1.2) - Dormant Products
Glucokise (Hexokise D or Hexokise 4 or GCK or EC 2.7.1.2) - Discontinued Products
Glucokise (Hexokise D or Hexokise 4 or GCK or EC 2.7.1.2) - Product Development Milestones
Featured News & Press Releases
Oct 14, 2020: Hua Medicine announces the drug manufacturing permit granted for Dorzagliatin
Sep 16, 2020: vTv Therapeutics to present additiol positive clinical study results from phase 2 Simplici-T1 study of TTP399 as adjunctive therapy for patients with type 1 diabetes at EASD Virtual Meeting
Jul 01, 2020: Hua Medicine announces positive 24-week topline results of phase III metformin combition trial of dorzagliatin
Jun 18, 2020: Hua Medicine successfully completes SEED (HMM0301), Dorzagliatin’s phase III Monotherapy trial
Jun 15, 2020: Hua Medicine’s Dorzagliatin demonstrates improvements in ?-Cell function in data presented at the American Diabetes Association’s 80th Scientific Sessions
Jun 13, 2020: vTv Therapeutics presents two late-breaking poster sessions on Simplici-T1 study at the American Diabetes Association’s Virtual Sessions supporting the potential of TTP399 as first-in-class oral adjunctive therapy for Type 1 Diabetes patients
May 31, 2020: Hua Medicine selected for inclusion in the MSCI Hong Kong Micro Cap Index
May 27, 2020: vTv Therapeutics to present full clinical study results from the positive phase 2 simplici-T1 study of TTP399, potential first-in-class oral adjunctive therapy for patients with type 1 diabetes at the American Diabetes Association’s 80th Virtual Scientific Sessions
Apr 27, 2020: Hua Medicine announces positive results of the combition study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor)
Feb 13, 2020: Hua Medicine appoints Dr. Fuxing Tang, a former U.S. FDA Officer, as Chief Technology Officer
Feb 10, 2020: vTv Therapeutics announces positive results from part 2 of the Phase 2 Simplici-T1 study of TTP399, potential first-in-class oral adjunctive therapy for patients with type 1 diabetes
Feb 07, 2020: vTv Therapeutics to host investor call and announce results from part 2 of the phase 2 Simplici-T1 Study of TTP399 - potential first-in-class oral adjunctive therapy for patients with Type 1 Diabetes
Jan 06, 2020: Hua Medicine announces positive results of HMM0110 and HMM0111
Nov 25, 2019: Hua Medicine’s global first-in-class drug was presented at 2019 Scientific Meeting of CDS
Nov 11, 2019: Hua Medicine’s pivotal phase III monotherapy trial of dorzagliatin, a dual-acting glucokise modulator, achieves primary efficacy endpoint in patients with type 2 diabetes
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by AstraZeneca Plc, H2 2020
Pipeline by Eli Lilly and Co, H2 2020
Pipeline by Hua Medicine Shanghai Ltd, H2 2020
Pipeline by Impetis Biosciences Ltd, H2 2020
Pipeline by Kriya Therapeutics Inc, H2 2020
Pipeline by Ligand Pharmaceuticals Inc, H2 2020
Pipeline by Merck & Co Inc, H2 2020
Pipeline by Pfizer Inc, H2 2020
Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H2 2020
Pipeline by vTv Therapeutics Inc, H2 2020
Dormant Projects, H2 2020
Discontinued Products, H2 2020